Abstract | OBJECTIVES: To study the safety and efficacy of continuous intratympanic dexamethasone-phosphate (Dex-P) for severe to profound sudden idiopathic sensorineural hearing (ISSHL) or sudden idiopathic anacusis after failure of systemic therapy. STUDY DESIGN: Randomized, double-blind, placebo controlled multicenter trial. METHODS: Patients with ISSHL and insufficient recovery (mean 4PTA = 97 dB HL) after systemic high dose glucocorticoid therapy received either Dex-P (4 mg/ml) or placebo (NaCl 0.9%) continuously applied for 14 days into the round window niche via a temporarily implanted catheter. For ethical reasons, intratympanic treatment was continued with Dex-P in all patients for another 14 days after the placebo-controlled study period. According to a two-step adaptive study design an interim analysis was performed after inclusion of 23 patients. RESULTS: Intention-to-treat analysis for the primary outcome criterion (4PTA: 0.5-3 kHz) during the placebo controlled study period (14 days) showed an average hearing improvement in the treatment group of 13.9 dB (SD: 21.3) and in the placebo group of 5.4 dB (SD: 10.4). This difference in hearing improvement between the two groups (mean: 8.4 dB, SD: 17.0, 95% CI: -7.1-24.1) was statistically not significant (p = .26). Of the secondary outcome parameters, the largest benefit of local salvage therapy was found for maximum speech discrimination with an improvement of 24.4% (SD: 32.0) in the treatment and 4.5% (SD: 7.6) in the placebo group (p = 0.07). After a 3 month follow-up period (i.e. after all patients received intratympanic Dex-P) hearing improvement in the two groups was very similar. No serious adverse events were observed. Sample size calculation after the interim analysis resulted in stopping of the trial. CONCLUSIONS: The tendency toward better hearing improvement in the treatment group, the rather conservative inclusion criteria, the limited placebo-controlled observation period and the absence of serious adverse events supports further investigation local inner ear drug delivery as a first or second line treatment option for ISSHL.
|
Authors | Stefan K Plontke, Hubert Löwenheim, Jürgen Mertens, Corinna Engel, Christoph Meisner, Andy Weidner, Rainer Zimmermann, Serena Preyer, Assen Koitschev, Hans-Peter Zenner |
Journal | The Laryngoscope
(Laryngoscope)
Vol. 119
Issue 2
Pg. 359-69
(Feb 2009)
ISSN: 1531-4995 [Electronic] United States |
PMID | 19172627
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Placebos
- Dexamethasone
|
Topics |
- Adult
- Aged
- Audiometry
- Catheterization
- Dexamethasone
(administration & dosage)
- Double-Blind Method
- Drug Administration Routes
- Female
- Glucocorticoids
(administration & dosage)
- Hearing Loss, Sensorineural
(drug therapy)
- Hearing Loss, Sudden
(drug therapy)
- Humans
- Male
- Middle Aged
- Placebos
- Round Window, Ear
- Treatment Failure
- Treatment Outcome
|